About Baronio Fund Opportunities Board Lab Directory Industry Partners Join PSRC Members Only
PSRC on Facebook PSRC on Instagram PSRC on Twitter PSRC on Youtube

Back to 2021 Virtual Presentations




Secondary lymphedema remains a debilitating sequelae of cancer therapy. Jerry F. Hsu @mr.jerryh and his co-authors at USC & City of Hope Plastic and Reconstructive Surgery continue the search for a pharmacological cure in the treatment of lymphedema. Human primary lymphatic endothelial cells (LECs) were harvested from discarded human foreskin tissue. Bexarotene, a selective retinoid x receptor agent, was administered in culture medium to LECs. Treated cells experienced an enhanced rate of proliferation, migration and 3D-tubular structure formation. Bexarotene’s pro-lymphangiogenic effects make it a promising agent for lymphedema therapy. Selective Activation of Retinoid-X-Receptor Activates Proliferation and Migration of Primary Human Lymphatic Endothelial Cells Jerry F. Hsu, BS @mr.jerryh; Roy P. Yu, BS @royyuu; Sun Young Park, MS; Wan Jiao, MD, PhD @jia.wan; Dongwon Choi, PhD; Eun Kyung Park, MS; Young-Kwon Hong, PhD; Alex K. Wong, MD @wongalexk

Back to 2021 Virtual Presentations